The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and impressive returns is undeniable, the linked risks are also notable. Many of thes